Skip to main content
. 2011 Oct 25;2011:937861. doi: 10.1155/2011/937861

Table 3.

Overview of studies with alternative strategies to protect from aminoglycoside ototoxicity. C: Chicken, CH: Chinchilla, G: Gerbil, GP: Guinea Pig, M: Mouse, R: Rat, X: in vitro, Y: in vivo; i.m.: intramuscular, i.v.: intravenous, i.p.: intraperitoneal, i.t.: intratympanic, s.c.: subcutaneous; d: day, h: hour, q12 h: every 12 h; O: no effect; P/PP/PPP: partial, not significant/partial and statistically significant/complete and statistically significant protection.

Therapy (dose) Aminoglycoside (dose) Species Outcome Reference
BDNF (10 ng/mL, 4 h) Gentamicin (2 mg/mL, 4 h) GP, X PP [213]
Dizocilpine (1 mg/kg/d, osmotic pump, 14 d)
Ifenprodil (10 mg/kg/d, osmotic pump, 14 d)
Neomycin (50 mg/kg, 1 x/d, s.c., 14 d) or
Kanamycin (250 mg/kg, 1 x/d, s.c., 21 d)
GP, Y PP
PP
[233]
Dizocilpine (1 mg/kg, 1 x/d, s.c.,10 d) Streptomycin (400 mg/kg, 1 x/d, s.c., 10 d) R, Y PP [234]
CTNF (0.44 g/kg, 1 x/d, s.c., 30 d) Gentamicin (80 mg/kg, 1 x/d, i.m., 30 d) GP, Y PP [249]
BDNF (1 μg, pellet in semicircular canal, with AG or 1 week later, over 1–8 weeks) Gentamicin (50 μg, pellet in semicircular canal, over 1–8 weeks) CH, Y P
TT
[246]
BDNF (100 μg/mL, local, pump @ 0.25 μL/h, 30 d)
NT-3 (100 μg/mL, local, pump @ 0.25 μL/h, 30 d)
Kanamycin (400 mg/kg, 1 x/d, i.p., 5 d) GP, Y O (BDNF)
PP (NT-3)
[248]
L-NAME (100 μM, 8 h)
BDNF (10 ng/mL, 8 h)
Gentamicin (2 mg/mL, 8 h) GP, X PP
PP
[247]
Isosorbide (1 mM, 8 h) Gentamicin (2 mg/mL, 8 h) GP, X PP [255]
MK 801 (1 mg/kg, 3 x before pump implantation) +/− NT-3 (local in pump @ 300 ng/h over 14 d) Amikacin (300 mM, local pump @ 5 μL/h, 24 h) GP, Y P (MK 801)
PP (MK + NT)
[256]
GDNF (10 μM, 72–96 h) Neomycin (0.6 mM, 72 h) R, X P (X) [250]
GDNF (50 ng/mL, local pump @ 0.5 μL/h or single dose 0.1 mg, i.t.) Kanamycin (200 mg/kg, s.c., single dose) + Ethacrynic Acid (40 mg/kg, i.v., single dose) GP, Y PP (Y)
GDNF + TGF-1, transgenic Kanamycin (150 mg/kg, s.c., single dose) + Ethacrynic Acid (40 mg/kg, i.v., single dose) GP, Y PP [257]
GDNF, transgenic Gentamicin (8 mg, i.t., single dose) GP, Y PP [258]
GDNF, transgenic Kanamycin (200 mg/kg, s.c., single dose) + Ethacrynic Acid (40 mg/kg, i.v., single dose) GP, Y PP [259]
Gentamicin (10 mg/kg, 1 x/d, i.m., 30 d) Gentamicin (160 mg/kg, 1 x/d, i.m., 10 d) GP, Y PP [230]
Amikacin (20 mg/kg, 1 x/d, i.m., 30 d) Amikacin (400 mg/kg, 1 x/d, i.m., 10 d) GP, Y PP [231]
2 Octave-band noise (81 dB SPL for 21 d) Gentamicin (445 μg, local to RWM over 14 d) G, Y P [232]
Ethacrynic Acid (40 mg/kg, i.v., single dose, 12–18 h ) Gentamicin (125 mg/kg, 1–20 injections q12h, i.m.) GP, Y PP [252]